NCT03689153 - A Study of JNJ-63733657 in Healthy Japanese Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 28, 2018

Primary Completion Date

July 11, 2019

Study Completion Date

July 11, 2019

Conditions

Healthy

Interventions

DRUG

JNJ-63733657

Single ascending IV low, middle, and high dose of JNJ-63733657 will be administered in sequential cohorts. The progression to the next (higher) dose level is dependent on acceptable safety and tolerability profile of JNJ-63733657 obtained after dose administration of the current dose level. The length of time between dosing days of cohorts will be at least 14 days.

DRUG

Placebo

Participants will receive matching placebo intravenously.

Trial Locations (1)

813-0017

Souseikai Fukuoka Mirai Hospital, Fukuoka